Molecular Medicine : MolMed to present its CDMO services at 2019 CAR-TCR Summit in Boston

PRESS RELEASE

MolMed to present its CDMO services at 2019 CAR-TCR Summit in Boston.

Milan (Italy), September 12th 2019 - MolMed S.p.A. (MLMD.MI) (the "Company"), biotechnology company focused on research, development, production and clinical validation of gene and cell therapies for the treatment of cancer and rare diseases, announces that today Luca Alberici, MolMed's Chief Business Officer, will present at the annual CAR TCR Summit held in Boston, MA, USA.

The world-renowned conference brings together over 1000 industry leaders developing CAR-TCR based therapies and joins pharma, biotech, regulatory bodies, academia, solution and service providers to discuss the next generation candidates beyond CD19, from solid tumor indications to autoimmune disorders.

MolMed takes part in the conference as one of the prominent players in the viral vector manufacturing market among the most innovative and next generation companies focusing on from bench to bedside services to bring CAR and TCR therapies to market.

Luca Alberici will explain the most innovative end-to-end solutions that MolMed is able to deliver to its clients in the rapidly growing field of cell & gene therapy, leveraging on its extensive experience in the CDMO business. Thanks to its proprietary processes for vectors and cells manufacturing and the manufacturing capacity of its 2 GMP facilities in Milan area - totaling 52,000 SQF and 26 grade B/C suites - MolMed is able to face a demand for viral vectors and genetically modified cells which is anticipated to increase significantly in the coming years.

More information on the event are available at https://car-tcr-summit.com/.

About MolMed

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed is the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies ex vivo for its proprietary products (Zalmoxis™) as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies.

MolMed's product portfolio includes proprietary anti-tumor therapies in both clinical and preclinical development: Zalmoxis™ (TK), is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Still focusing on this cell & gene technology, the Company is developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, which in March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase. The product, whose innovative spacer incorporated in the CAR protein received in May 2019 the confirmation of grant, is potentially effective also in several epithelial solid tumors. MolMed is also developing a pipeline based on NK (Natural Killer) cells, following a research agreement signed in 2018 with Glycostem. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

FROM GENES TO THERAPY

1

For further information:
Ilaria Candotti	Tommasina Cazzato
Investor Relations & Communication Manager	Press Office
MolMed S.p.A.	Community Group
+39 02 21277.205	[phone]
[e-mail]	[e-mail]

FROM GENES TO THERAPY

2